Plasma Fractionation Market worth $52.58 billion in 2031
The report "Plasma Fractionation Market by Product (Immunoglobulins [Intravenous, Subcutaneous], Albumin, Protease Inhibitors, VWF), Application (Preclinical, Therapeutics), Therapy (Neurology, Immunology, Hematology, Rheumatology), Region - Global Forecast to 2031" is expected to reach USD 52.58 billion in 2031 from USD 36.44 billion in 2026, at a CAGR of 7.6% during the forecast period.
Browse 517 market data Tables and 53 Figures spread through 420 Pages and in-depth TOC on "Plasma Fractionation Market by Product (Immunoglobulins [Intravenous, Subcutaneous], Albumin, Protease Inhibitors, VWF), Application (Preclinical, Therapeutics), Therapy (Neurology, Immunology, Hematology, Rheumatology), Region - Global Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/plasma-fractionation-market-93798284.html
The plasma fractionation market is growing significantly, driven by rising demand for immunoglobulins in immunology and neurology, strategic expansion of plasma collection capacity by market players, and greater use of plasma-derived therapies. Immunoglobulins, albumin, coagulation factor concentrates, protease inhibitors, and other plasma-derived products are widely used across therapeutic applications, including neurological, immunological, hematological, critical-care, and pulmonary conditions. The expansion of plasma collection networks and investments in fractionation and manufacturing infrastructure are further supporting market growth, particularly as market participants seek to improve plasma utilization and ensure a reliable product supply. However, the market continues to face challenges, including high treatment costs and reimbursement constraints for plasma-derived products, which can limit patient access and adoption in price-sensitive healthcare markets.
By product, immunoglobulins are expected to register the highest CAGR during the forecast period.
By product, the plasma fractionation market is segmented into immunoglobulins, coagulation factor concentrates, albumin, protease inhibitors, and other plasma products. The immunoglobulins segment is expected to register the highest CAGR over the forecast period, driven by rising demand for IVIG, SCIG, and other immunoglobulins for immunological and neurological conditions. Growing diagnosis of primary immunodeficiencies, autoimmune disorders, and immune-mediated neurological diseases, along with recurring treatment requirements, is supporting demand for immunoglobulin therapies. Expanding plasma collection and fractionation capacity and increasing investments in immunoglobulin manufacturing are further expected to support this segment's growth.
By application, therapeutics is expected to register the highest CAGR during the forecast period.
By application, the plasma fractionation market is segmented into therapeutics and academic & preclinical research. The therapeutics segment is expected to register the highest CAGR over the forecast period, driven by the growing clinical use of plasma-derived products across immunology, neurology, hematology, critical care, pulmonology, hemato-oncology, and rheumatology. Growing demand for immunoglobulins, coagulation factor concentrates, albumin, and protease inhibitors, along with rising prevalence of conditions requiring plasma-derived therapies and increasing healthcare utilization, is supporting the growth of therapeutic applications. Continued investments in plasma collection, fractionation capacity, and manufacturing infrastructure are expected to further support the expansion of this segment.
By region, North America accounted for the largest share of the plasma fractionation market in 2025.
In 2025, North America held the largest share of the plasma fractionation market, supported by established plasma collection networks, high utilization of plasma-derived therapies, advanced healthcare infrastructure, and substantial fractionation and manufacturing capabilities. The region benefits from strong demand for immunoglobulins and other plasma-derived products, major market players, and extensive source-plasma collection infrastructure. Continued investments in plasma collection, domestic manufacturing, and advanced fractionation technologies are expected to sustain the region's leading position.
Leading players in the market include CSL (Australia), Takeda Pharmaceutical Company Limited (Japan), Grifols, S.A. (Spain), Octapharma AG (Switzerland), Kedrion S.p.A. (Italy), LFB (France), ADMA Biologics, Inc. (USA), Sanquin (Netherlands), Taibang Biological Group Co., Ltd. (China), GC Biopharma Corporate (South Korea), Hualan Bioengineering Inc. (China), Japan Blood Products Organization (Japan), Emergent (USA), Shanghai RAAS Blood Products Co., Ltd. (China), and Intas Pharmaceuticals Ltd. (India), among others.
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Plasma Fractionation Market
- What will your New Revenue Sources be
- Who will be your Top Customer; what will make them switch
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
